In May 2018 Health Canada announced the results of its second safety review of Magnevist, MultiHance, Omniscan, and Optimark, as well as other gadolinium contrast injections for MRIs, CT scans, and other radiology procedures. In May 2018 Health Canada issued this document, “Summary Safety Review – Gadolinium based contrast agents – Assessing the … [Read more...]
MRI Contrast Agents: Gadolinium Retention Warnings Added To Drug Label
The gadolinium contrast agents safety warnings announced by the FDA in December 2017 started to be seen on new drug labels approved in the spring of 2018. It is important to understand that symptoms of gadolinium-related medical conditions can first appear anywhere from just a few hours until several weeks after the MRI or MRA procedure when a … [Read more...]
Gadolinium Deposition Disease Explained: How It Is Diagnosed, And More
A person who received an injection of a gadolinium-based contrast agent (GBCA) may develop some medical conditions following their MRI or MRA procedure which could be symptoms of gadolinium deposition disease. These various gadolinium-related symptoms include: Persistent headache; “Brain fog”; Skin that appears spongy or rubbery, … [Read more...]
FDA And MHRA Actions For Gadolinium-Containing Contrast Agents Differ
There is a difference between the United States FDA and the United Kingdom MHRA in terms of the regulatory actions being taken with respect gadolinium-based contrast agents (GBCAs). The drug safety issue is that low levels of gadolinium can be retained in the brain and other tissuesfor months to years after the administration of these drugs for … [Read more...]